~~<i id='B7F9A29634'><strike id='B7F9A29634'><tt id='B7F9A29634'><pre id='B7F9A29634'></pre></tt></strike></i>~~

Home» explore» focus

focus

author：leisure time 2025-09-28 00:17:35 Page View：3

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Amylyx ALS drug fails large clinical trial
Next article： Dobbs anniversary: the lost opportunity of abortion as health care

leisure time

Medical records are filled with copy

AdobeIrecentlytookcareofapatientwhosemedicalrecordsincludedmultiplenotesaboutherpastopen-heartsurger

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

Whyareaddictiontreatmentssohardtoget?Cansmallcompaniescompeteinobesity?Andsincewhenis“SeriesE”athing

Drug repurposing or repositioning? The language matters

AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

A deep dive into Applied Therapeutics’ data, and questions on Cassava

MollyFerguson/STATHaveyouheardthenews?I’mlaunchingaweeklyemailnewsletterstartingonMarch28.It’scalled

WSS

focus

focus

Wikipedia

leisure time

A deep dive into Applied Therapeutics’ data, and questions on Cassava